International Stem Cell ISCO
OTC ISCO
$0.27 +0.01 (+3.85%)
At close: Oct 15, 2026 · 4:00 PM EDT

International Stem Cell (ISCO) Non-Current Debt (2019 - 2020)

Updated

International Stem Cell's Non-Current Debt was $2.48 million in Q4 2020, up 4.4% from $2.37 million a year earlier.

Analysis

International Stem Cell (ISCO) Non-Current Debt (2019 - 2020) Analysis & Trends

  • In earlier years, Non-Current Debt was $2.37 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 37.34 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 62.48 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 23.68 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 23.83 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 60.50 Bn
10 International Stem Cell 2.08 Mn -1.89 Mn 1.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 2.48 Mn
Dec 31, 2019 2.37 Mn
API Access

International Stem Cell Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=ISCO&period=max&api_key=YOUR_API_KEY